Ranbaxy Seller To Pump Funds Into India’s Fortis, Religare
This article was originally published in PharmAsia News
Executive Summary
The seller of Ranbaxy Laboratories plans to use some of the proceeds from Japan's Daiichi Sankyo to make India's Religare and Fortis health care companies industry leaders in India. Ranbaxy CEO Malvinder Singh said that for the next several years, Ranbaxy would focus on becoming the No. 1 health care company in the country. In the long run, he said, the plan is to phase in Fortis as an international company. He rejected speculation Fortis would be combined with the Anil Ambani group. (Click here for more
You may also be interested in...
Japanese Firms Pursued Over Edirol Ingredient
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
Who’s Hired? Apotex Names New US President & CEO
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
Need a specific report? 1000+ reports available
Buy Reports